Clinical Trial Evaluating Oral Drug against Coronavirus Expected to Start Later This Spring
April 27, 2020 | Biotechnology
Reading time: 6 minutes
Lab.Equipment has sourced a new article from the Biotechnology industry for you. This one is published by GEN – Genetic Engineering and Biotechnology News:
Clinical studies evaluating an antiviral drug that is in development against SARS-CoV-2 are expected to begin later this spring. Scientists working to develop the drug, which is called EIDD-2801, suggest that if trials are successful, the drug could not only be used to limit the spread of SARS-CoV-2, but could also control future outbreaks of other emerging coronaviruses. EIDD-2801 is an orally available form of the antiviral compound EIDD-1931, which has shown promise in reducing lung damage in animal models.
Researchers at the University of North Carolina (UNC) at Chapel Hill Gillings School of Global Public Health are playing a key role in the development and testing of EIDD-2801. The team, together with U.S. collaborators, has now reported on results from tests evaluating the drug in cultured human lung cells infected with SARS-CoV-2, as well as in mice infected with the related coronaviruses SARS-CoV (severe acute respiratory syndrome-coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus). Their results showed that, when used prophylactically, or admi... Read the whole article at the GEN – Genetic Engineering and Biotechnology News Blog.
In the Bio Technology industry and are looking for robust Bio tech lab equipment for your laboratory? Go through Lab.Equipment’s broad selection of biotech equipment built by established MFGs like:
Find robust and multifunction Biotech lab products to meet your application requirements from our product portfolio that includes: